$NTEC News
Last published 5y ago
- 5y agoNTECINDPIntec Closes Merger with Decoy BiosystemsPR NewswireNEW YORK, Aug. 3, 2021 /PRNewswire/ -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company," and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ("Decoy") and the
- 5y agoNTECIntec Announces Expected Closing Date of Decoy MergerPR NewswireJERUSALEM, Aug. 3, 2021 /PRNewswire/ -- Intec Parent, Inc. (NASDAQ:NTEC) ("Intec Parent" or the "Company"), today announced that the pending and previously announced reverse merger (the "Decoy Merger") with Decoy Biosystems, Inc. ("Decoy") is currently e
- 5y agoCYTHFSRNTECSUPN+1Thinking about buying stock in Fisker, Torchlight Energy, Intec Pharma, Supernus Pharmaceuticals, or Cyclo Therapeutics?PR NewswireNEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FSR, TRCH, NTEC, SUPN, and CYTH. T
- 5y agoARNACARAJAZZNTECRapid Development of Cannabinoid Based Medicinal Products Reaching New LevelsPR NewswirePALM BEACH, Fla., June 8, 2021 /PRNewswire/ -- The recent pandemic has, as we all know, negatively affected almost every business and financial markets across the globe… and even the seemingly ever increasing Cannabidiol markets. The global COVID-1
- 5y agoDDDIGTNTECPRPO+1Thinking about buying stock in Intec Pharma, Energous Corp, International Game Technology, 3D Systems, or Precipio?PR NewswireNEW YORK, May 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NTEC, WATT, IGT, DDD, and PRPO. To s
- 5y agoNTECKSUSNXSPRTMoore Kuehn Encourages NTEC, KSU, SNX, and SPRT Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 5y agoNTECIntec Pharma Announces Filing of 2020 Annual Report on Form 10-KGlobeNewswireJERUSALEM , March 16, 2021 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that it has filed its annual report on Form 10-K for the year ended...
- 5y agoNTECIntec Pharma and Decoy Biosystems Announce Merger AgreementPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") announced today that it has entered into a definitive agreement for a business...
- 5y agoNTECIntec Pharma Announces Cannabinoid Research Collaboration with GW PharmaPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a feasibility agreement with GW Research Limited...
- 6y agoNTECIntec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate UpdatePR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended September 30, 2020 and...
- 6y agoNTECIntec Pharma Announces 1-for-20 Reverse Share SplitPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The...
- 6y agoNTECIntec Pharma Announces New Research Collaboration Agreement with MSDPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the...
- 6y agoNTECIntec Pharma to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech SummitPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the virtual Oppenheimer Fall...
- 6y agoNTECIntec Pharma to Present at H.C. Wainwright 22nd Annual Global Investment ConferencePR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the virtual H.C. Wainwright...
- 6y agoNTECIntec Pharma Announces Pricing of $4.9 Million Registered Direct OfferingGlobeNewswireJERUSALEM, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into a definitive agreement with Aspire Capital Fund...
- 6y agoNTECIntec Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate UpdatePR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the second quarter ended June 30, 2020 and provides ...
- 6y agoNTECIntec Pharma to Present at Jefferies Virtual Healthcare ConferencePR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the Jefferies Virtual...
- 6y agoNTECIntec Pharma Reports First Quarter 2020 Financial Results and Provides Corporate UpdatePR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the first quarter ended March 31, 2020 and provides ...
- 6y agoNTECIntec Pharma Announces $5.0 Million Registered Direct OfferingGlobeNewswireJERUSALEM , May 04, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into definitive agreements with several institutional...
- 6y agoNTECIntec Pharma Reports Fourth Quarter and Year End 2019 Financial Results and Corporate UpdatePR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2019 ...
- 6y agoNTECIntec Pharma to Participate at Three Investment Conferences in MarchPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming...
- 6y agoNTECIntec Pharma Announces Pricing of $6.5 Million Public OfferingGlobeNewswireJERUSALEM, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of...
- 6y agoNTECIntec Pharma Announces Proposed Public OfferingPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that it intends to offer and sell a combination of ordinary shares (or...
- 6y agoNTECIntec Pharma Issues Letter to ShareholdersPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today provides a business and clinical update on its development programs with the...
- 6y agoNTECIntec Pharma Provides Update on Novartis Feasibility and Option AgreementPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for ...
- 6y agoNTECIntec Pharma to Present at LD Micro's 12th Annual Main EventPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will be participating in the 12th Annual LD...
- 6y agoNTECIntec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire CapitalPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement...
- 7y agoNTECIntec Pharma to Participate in Jefferies London Healthcare ConferencePR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate in the Jefferies London...
- 7y agoNTECIntec Pharma Reports Third Quarter 2019 Financial Results and Provides Business UpdatePR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and nine months ended September 30, 2019. ...
- 7y agoNTECIntec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder SocietyPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the Company's Phase 3 clinical...
- 7y agoNTECIntec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder SocietyPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters in support of the Company's Phase 3 clinical development ...
- 7y agoNTECIntec Pharma to Participate in September Investment ConferencesPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming...
- 7y agoNTECIntec Pharma Reports Second Quarter 2019 Financial Results and Business UpdatePR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and six months ended June 30, 2019....
- 7y agoNTECIntec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease PatientsPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces top-line data from the Company's pivotal Phase 3 trial (the ACCORDANCE...
- 7y agoNTECIntec Pharma Announces Publication of Article Reviewing Accordion Pill's Unique Gastric Retention Platform in Therapeutic DeliveryPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that a review highlighting the benefits of the Accordion Pill® (AP) oral...
- 7y agoNTECIntec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related DisordersPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier Phase 2 clinical study of the Accordion...
- 7y agoNTECIntec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related DisordersPR NewswireIntec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that results from a pharmacokinetics (PK) study of the Accordion...
- 14y agoNTECCRNTPLXIsrael Stocks: Protalix, Biocell, Ceragon, Delta-Galil, MedigusBloombergIsrael’s TA-25 index slid to its lowest in more than a week, declining 0.7 percent to 1,158.65 at the 4:30 p.m. close in Tel Aviv. Investors traded about 1 billion shekels ($264 million) of shares and convertible securities, according to bourse data.